Selected research
Industry Research
Liraglutide for The Treatment of Diabetes and Obesity Industry Research Report 2026
Market perspective
The global Liraglutide for The Treatment of Diabetes and Obesity market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Liraglutide for The Treatment of Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Liraglutide for The Treatment of Diabetes and Obesity is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Liraglutide for The Treatment of Diabetes and Obesity is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Liraglutide for The Treatment of Diabetes and Obesity include Huadong Medicine, Sino Biopharm, Teva and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Liraglutide for The Treatment of Diabetes and Obesity market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liraglutide for The Treatment of Diabetes and Obesity Market by Company
Huadong Medicine
Sino Biopharm
Teva
Novo Nordisk
Liraglutide for The Treatment of Diabetes and Obesity Segment by Type
Generic Drug
Original Drug
Liraglutide for The Treatment of Diabetes and Obesity Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Liraglutide for The Treatment of Diabetes and Obesity Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liraglutide for The Treatment of Diabetes and Obesity market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liraglutide for The Treatment of Diabetes and Obesity and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liraglutide for The Treatment of Diabetes and Obesity.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Liraglutide for The Treatment of Diabetes and Obesity manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Liraglutide for The Treatment of Diabetes and Obesity by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Liraglutide for The Treatment of Diabetes and Obesity in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Generic Drug
- Original Drug
Applications
- Hospital and Clinic
- Retail Pharmacies
- Other
Companies covered
- Huadong Medicine
- Sino Biopharm
- Teva
- Novo Nordisk
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size (2021-2032)
- 2.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales (2021-2032)
- 2.2.3 Global Liraglutide for The Treatment of Diabetes and Obesity Market Average Price (2021-2032)
- 2.3 Liraglutide for The Treatment of Diabetes and Obesity by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Generic Drug
- 2.3.3 Original Drug
- 2.4 Liraglutide for The Treatment of Diabetes and Obesity by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital and Clinic
- 2.4.3 Retail Pharmacies
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue of Manufacturers (2021-2026)
- 3.4 Global Liraglutide for The Treatment of Diabetes and Obesity Average Price by Manufacturers (2021-2026)
- 3.5 Global Liraglutide for The Treatment of Diabetes and Obesity Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Liraglutide for The Treatment of Diabetes and Obesity, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Liraglutide for The Treatment of Diabetes and Obesity, Product Type & Application
- 3.8 Global Manufacturers of Liraglutide for The Treatment of Diabetes and Obesity, Established Date
- 3.9 Global Liraglutide for The Treatment of Diabetes and Obesity Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Huadong Medicine
- 4.1.1 Huadong Medicine Company Information
- 4.1.2 Huadong Medicine Business Overview
- 4.1.3 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
- 4.1.5 Huadong Medicine Recent Developments
- 4.2 Sino Biopharm
- 4.2.1 Sino Biopharm Company Information
- 4.2.2 Sino Biopharm Business Overview
- 4.2.3 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
- 4.2.5 Sino Biopharm Recent Developments
- 4.3 Teva
- 4.3.1 Teva Company Information
- 4.3.2 Teva Business Overview
- 4.3.3 Teva Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Teva Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
- 4.3.5 Teva Recent Developments
- 4.4 Novo Nordisk
- 4.4.1 Novo Nordisk Company Information
- 4.4.2 Novo Nordisk Business Overview
- 4.4.3 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
- 4.4.5 Novo Nordisk Recent Developments
5 Global Liraglutide for The Treatment of Diabetes and Obesity Market Scenario by Region
- 5.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region: 2021-2032
- 5.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region: 2021-2026
- 5.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region: 2027-2032
- 5.3 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region: 2021-2032
- 5.3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region: 2021-2026
- 5.3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region: 2027-2032
- 5.4 North America Liraglutide for The Treatment of Diabetes and Obesity Market Facts & Figures by Country
- 5.4.1 North America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2032)
- 5.4.3 North America Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Liraglutide for The Treatment of Diabetes and Obesity Market Facts & Figures by Country
- 5.5.1 Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2032)
- 5.5.3 Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Facts & Figures by Country
- 5.6.1 Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Liraglutide for The Treatment of Diabetes and Obesity Market Facts & Figures by Country
- 5.7.1 South America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2032)
- 5.7.3 South America Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2032)
- 6.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Type (2021-2032)
- 6.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Type (2021-2032)
- 6.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Type (2021-2032)
- 6.3 Global Liraglutide for The Treatment of Diabetes and Obesity Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2032)
- 7.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Application (2021-2032)
- 7.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Application (2021-2032)
- 7.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Application (2021-2032)
- 7.3 Global Liraglutide for The Treatment of Diabetes and Obesity Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Liraglutide for The Treatment of Diabetes and Obesity Value Chain Analysis
- 8.1.1 Liraglutide for The Treatment of Diabetes and Obesity Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Liraglutide for The Treatment of Diabetes and Obesity Production Mode & Process
- 8.2 Liraglutide for The Treatment of Diabetes and Obesity Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Liraglutide for The Treatment of Diabetes and Obesity Distributors
- 8.2.3 Liraglutide for The Treatment of Diabetes and Obesity Customers
9 Global Liraglutide for The Treatment of Diabetes and Obesity Analyzing Market Dynamics
- 9.1 Liraglutide for The Treatment of Diabetes and Obesity Industry Trends
- 9.2 Liraglutide for The Treatment of Diabetes and Obesity Industry Drivers
- 9.3 Liraglutide for The Treatment of Diabetes and Obesity Industry Opportunities and Challenges
- 9.4 Liraglutide for The Treatment of Diabetes and Obesity Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst